Independent information portal

Your pharmaceutical product. Your Swiss MAH pathway.

Planning a Swiss launch without your own local affiliate? Define the authorisation-holder model, retained responsibilities and partner scope before you appoint a provider. Start with your product and your next decision.

Discuss your Swiss market entry
  • Swiss domicile and appropriate authorisations
  • Documented quality and pharmacovigilance responsibilities
  • Named specialists and contractual scope

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@mahswitzerland.com

Illustrative portrait of a regulatory specialist in a bright office
Transfer planningCoordinate the holder change and continuity of supply

For pharmaceutical companies, biotech teams and product owners

Define your Swiss operating model before choosing a partner

A useful MAH discussion starts with who will own each responsibility. Compare your retained capabilities with the functions you want a Swiss partner to manage, including what happens when the arrangement changes.

Use the evidence in context. Use a written scope when comparing proposals: named responsibilities, evidence of suitability, fees, dependencies, escalation and exit arrangements. This portal receives enquiries; provider appointments are agreed separately.

Looking for a Swiss MAH partner?

Tell us whether you are planning your first Swiss launch, comparing local operating models or reviewing an existing arrangement. Detailed qualification can follow the first contact.

Discuss your Swiss market entry

What to verify with a Swiss MAH provider

  • Swiss domicile and appropriate authorisationsCheck the Swiss register entry and the licences required for the proposed activities.
  • Documented quality and pharmacovigilance responsibilitiesRequest the quality agreement, safety responsibilities and documented escalation routes.
  • Named specialists and contractual scopeReview the named specialists, deputies, scope and allocation of liability before signing.

Services

Eight things a foreign company needs in Switzerland

Switzerland is not part of the EU single market and not covered by an EU marketing authorisation. Every medicine needs its own Swissmedic authorisation, held by a company with a Swiss domicile. These are the eight functions external providers take over, together or separately.

How onboarding works

From first call to Swiss holder in four steps

Describe your product, dossier status and support needs. Enquiries reach the website operator at info@mahswitzerland.com. Provider qualifications, availability and contracts must be checked separately.

  1. Scoping call and gap checkWeek 1

    External providers look at your dossier, your target dispensing category and your supply chain, then tell you which Swiss procedure fits: full authorisation, an Art. 13 HMG submission using foreign assessment results, simplified authorisation, or a transfer of an existing Swiss authorisation. You get a written scope, a fee estimate and a named contact in Switzerland.

  2. Contract, quality agreement, responsibilitiesWeeks 2 to 4

    External providers sign a service agreement plus a technical or quality agreement that names who does what: holder duties, pharmacovigilance, batch release, complaints, recalls, product information maintenance. This is the document a Swissmedic inspector asks for first, so external providers write it to be inspected.

  3. Submission or transferWeeks 4 to 12

    External providers build or convert the Swiss part of the dossier: Swiss product information in German, French and Italian, labelling, the Swiss application forms and the electronic submission through Swissmedic's portal. For an existing Swiss authorisation, external providers file the change of holder instead and keep the product supplied throughout.

  4. Market release and maintenanceOngoing

    Once the authorisation is in their name external providers run the yearly duties: variations, renewals, annual fees, pharmacovigilance including ElViS reporting and safety reports, batch release, artwork changes and, if you want it, SL pricing and distribution. You get one quarterly report per product.

Illustrative scene of regulatory professionals reviewing a dossier
One named contactYour file has a person, not a ticket queue.

Swiss market context

  • 9Mpeople, four national languages
  • CHF 7bnmedicines market at ex-factory prices
  • 5 yearsvalidity of a Swissmedic authorisation
  • 3 languagesmandatory product information
  • 4language versions of this portal

Packages

Three ways to work with the providers

Every product is scoped individually, but the shape of the mandate is usually one of these three. The difference is how much of the Swiss operation you keep and how much external providers own.

  • Essential MAH

    External providers hold the authorisation, you keep commercial control

    • external MAH providers as Zulassungsinhaberin on the Swissmedic certificate
    • Regulatory maintenance: variations, renewals, annual fees, correspondence with Swissmedic
    • Swiss product information and labelling in German, French and Italian
    • Pharmacovigilance base service with a named RPPV and ElViS reporting
    • One named regulatory contact and a quarterly product report

    Best for companies with their own distributor in Switzerland who only lack a legal holder.

    Get a quote
  • MAH plus PV and QA

    Holder, safety and quality in one hand

    • Everything in Essential MAH
    • Full pharmacovigilance system: RPPV, PSMF contribution, signal handling, safety reports, literature screening
    • Quality system for the Swiss market: complaint handling, deviations, recalls, self-inspection
    • Batch release for the Swiss market by their Qualified Person
    • Import and wholesale under their Swissmedic establishment licence

    Best for companies without a Swiss quality or safety function, which is most first-time entrants.

    Get a quote
  • Full CCO

    External providers hold, supply and commercialise

    • Everything in MAH plus PV and QA
    • Pricing and reimbursement: SL application to the FOPH, price defence, three-year reviews
    • Distribution set-up with a Swiss wholesaler and hospital tenders
    • Order to cash, customer service and medical information in three languages
    • Market access and stakeholder work, transfer-pricing model agreed up front

    Best for orphan and specialty products where a full Swiss affiliate is not worth building.

    Get a quote

External providers quote fixed annual fees per product plus an hourly rate for project work, never a share of your revenue as a default. What moves the price: number of products and pack sizes, whether the dossier already exists in Switzerland, the dispensing category, how many variations per year your product generates, whether SL listing and distribution are in scope. Ask for a quote and you get a written fee schedule on a timetable agreed with the selected provider.

Case studies

Illustrative scenarios, not client results

Illustrative scenarios, not client results

  • US biotech, orphan drug

    Swiss holder for a rare disease product without a Swiss entity
    Situation
    A US company with an EU authorisation and roughly 40 Swiss patients wanted the product available in Switzerland but could not justify founding a Swiss subsidiary, hiring an RPPV and a Qualified Person for one product.
    What we did
    External providers submitted the Swiss application using the foreign assessment results under Art. 13 HMG, prepared product information in three languages, became the holder and set up pharmacovigilance and Swiss batch release. After approval external providers filed the SL application with the FOPH and negotiated the price with an international price comparison and a therapeutic cross-comparison.
    Result
    Authorisation and reimbursement in the same calendar year as the submission, one Swiss point of contact for the treating centres, no Swiss headcount for the client.
  • EU generics company

    Twelve authorisations transferred without a supply gap
    Situation
    A European generics manufacturer sold a portfolio of twelve Swiss authorisations and needed the holder changed quickly, while keeping the products on pharmacy shelves and on the Spezialitätenliste.
    What we did
    External providers ran the twelve holder changes as one project with a single communication line to Swissmedic, sequenced artwork and product information updates so no pack had to be withdrawn, and coordinated the SL entries with the FOPH so the price and the listing survived the change.
    Result
    All twelve authorisations transferred within one review cycle, no interruption of supply, no delisting, artwork changed at the next planned print run instead of an emergency reprint.
  • Asian manufacturer, first Swiss product

    From establishment licence question to first delivery
    Situation
    An Asian manufacturer had a partner for sales in Switzerland but no licensed importer, no Swiss holder and no idea which dispensing category their product would get.
    What we did
    External providers clarified the classification with Swissmedic before submission, held the authorisation, imported under their own establishment licence with their responsible person, and released each batch for the Swiss market through their Qualified Person after checking the manufacturer's certificates against the Swiss requirements.
    Result
    First commercial delivery to the Swiss wholesaler eleven weeks after approval, a clean GDP audit trail from the plant to the wholesaler, and a client who never had to apply for a licence of their own.

Questions buyers ask before they call

  • Do we need a Swiss company to hold a Swissmedic authorisation?

    You need a holder with a Swiss domicile. Art. 10 HMG requires the applicant to have a domicile, a registered office or a branch in Switzerland. Either you found a Swiss entity or you appoint an established Swiss company with the appropriate authorisations as Zulassungsinhaberin. Appointing an existing holder removes the cost of a legal entity, an RPPV, a Qualified Person and a Swiss quality system.

  • Is an EU marketing authorisation valid in Switzerland?

    No. Switzerland is not in the EU or the EEA, and neither a centralised EMA authorisation nor a national EU authorisation is valid here. You need a separate Swissmedic authorisation. Art. 13 HMG does require Swissmedic to take account of the assessment results of a foreign authority with comparable controls, which shortens the work but does not replace the Swiss application.

  • How long does a Swiss authorisation take?

    Plan on a first submission in weeks 4 to 12 of a project and then Swissmedic clock time on top. The standard procedure for a new active substance runs to several hundred days of authority time plus your answer time; simplified procedures, procedures using foreign assessment results and changes are much faster. A transfer of an existing authorisation is the quickest route to a Swiss holder.

  • What does a Swiss MAH service cost?

    External providers quote a fixed annual holder fee per product plus project fees for submissions, variations and transfers. The drivers are the number of products and packs, the dispensing category, the dossier status in Switzerland, the number of variations your product generates and whether pharmacovigilance, batch release, SL pricing and distribution are in scope. Swissmedic fees and the annual authorisation fee are charged on at cost.

  • Who owns the authorisation if we change partners later?

    You do, commercially. The Swissmedic certificate names external MAH providers as holder, and their contract obliges the providers to transfer the authorisation to you or to a third party you name, with their full cooperation and the dossier in a usable format. External providers have run these exits in both directions and they are part of the standard agreement, not a negotiation at the end.

  • Do you also handle pricing and reimbursement?

    Yes. Listing on the Spezialitätenliste is a separate procedure at the Federal Office of Public Health, not at Swissmedic. External providers prepare the application, build the international price comparison and the therapeutic cross-comparison, defend the price in the review and handle the three-year reviews and the resulting price cuts.

  • Can you import and release the product as well?

    Yes. External providers hold a Swissmedic establishment licence with a named responsible person, so external providers can import and wholesale in Switzerland, and their Qualified Person releases batches for the Swiss market. That means one contract instead of a holder, an importer and a release service.

  • Which languages do you work in, and which does the law require?

    External providers work in German, English and French. Swiss product information and packaging must be available in German, French and Italian, so external providers commission and control the Italian versions as part of the mandate. Your correspondence with the providers can stay in English throughout.

Sources

Tell the providers what you want to launch in Switzerland

Send the product, the dossier status and your target date. You get a written scope, a fee schedule and the name of the person who would run your file, on a timetable agreed with the selected provider.

Enquire about Swiss MAH support

Public Swiss sources, independent explanations, and enquiries about external specialist services.

Get a Swiss MAH quote
  • Independent information portal
  • Public Swiss sources, independent explanations, and enquiries about external specialist services.
Get a quote

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@mahswitzerland.com